Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer in part due to inherent resistance to chemotherapy, including the first-line drug gemcitabine. Although low expression of the nucleoside transporters hENT1 and hCNT3 that mediate cellular uptake of gemcitabine has been linked to gemcitabine resistance, the mechanisms regulating their expression in the PDAC tumor microenvironment are largely unknown. Here, we report that the matricellular protein cysteine-rich angiogenic inducer 61 (CYR61) negatively regulates the nucleoside transporters hENT1 and hCNT3. CRISPR/Cas9-mediated knockout of CYR61 increased expression of hENT1 and hCNT3, increased cellular uptake of gemcitabine and sensitized PDAC cells to gemcitabine-induced apoptosis. In PDAC patient samples, expression of hENT1 and hCNT3 negatively correlates with expression of CYR61. We demonstrate that stromal pancreatic stellate cells (PSCs) are a source of CYR61 within the PDAC tumor microenvironment. Transforming growth factor-β (TGF-β) induces the expression of CYR61 in PSCs through canonical TGF-β-ALK5-Smad2/3 signaling. Activation of TGF-β signaling or expression of CYR61 in PSCs promotes resistance to gemcitabine in PDAC cells in an in vitro co-culture assay. Our results identify CYR61 as a TGF-β-induced stromal-derived factor that regulates gemcitabine sensitivity in PDAC and suggest that targeting CYR61 may improve chemotherapy response in PDAC patients.
Introduction
PDAC is the fourth leading cause of cancer death in the United States, with more than 40 000 patient deaths per year (1) . Moreover, PDAC is projected to become the second leading cause of cancer death by 2030 due to a rising incidence and the lack of improvement in survival compared with other cancers (2) . PDAC has one of the lowest 5-year survival rates at 6% (1), underscoring the need for better treatment options. Gemcitabine is a nucleoside pyrimidine analog that has long been the backbone of chemotherapy for PDAC, both as a single agent, and more recently, in combination with nab-paclitaxel. Gemcitabine is utilized in first-and second-line treatment for locally advanced and metastatic PDAC, as well as adjuvant therapy for these patients. Incorporation of gemcitabine into DNA results in masked-chain termination, which stops DNA synthesis and induces apoptosis of the cell (3) . Although gemcitabine is one of the most commonly used treatments for PDAC, as a single agent it prolongs median survival by just over a month and is not effective for all patients (4) . Attempts to enhance gemcitabine efficacy with targeted agents or other cytotoxic agents, with the exception of nab-paclitaxel, have had limited success (5) .
Because gemcitabine is hydrophilic, it must be transported through the hydrophobic cell membrane by transmembrane nucleoside transporters. The equilibrative nucleoside transport family mediates bidirectional transport of nucleosides across the plasma membrane along the concentration gradient, whereas the concentrative nucleoside transport family concentrates nucleosides in the cell by coupling transport with cations (6, 7) . Human equilibrative nucleoside transporter-1 (hENT1) and human concentrative nucleoside transporter-3 (hCNT3) both have important roles in the cellular uptake of the nucleoside analog gemcitabine (8) . Consistent with this role, PDAC patients with low expression of hENT1 and hCNT3 have significantly worse survival after gemcitabine treatment compared with patients with high hENT1 and hCNT3 expression (9) (10) (11) (12) . Although hENT1 expression is currently being evaluated as a biomarker to predict patient response to gemcitabine (13) , the molecular mechanisms regulating hENT1 and hCNT3 expression in the PDAC tumor microenvironment are largely unknown. Recent studies suggest that epithelial-to-mesenchymal transition (EMT) (14) and ErbB2 expression (15) negatively regulate hENT1 and hCNT3 expression, but further studies are needed to identify mechanisms that regulate their expression in PDAC cells in the context of the tumor microenvironment. Here, we investigate factors regulating hENT1 and hCNT3 expression in the PDAC tumor microenvironment.
Methods and materials
Cell culture and reagents PANC1, MiaPaCa-2, BxPC3, CFPAC-1 and 293T cells were obtained from American Type Culture Collection (Manassas, VA) and were verified by Short Tandem Repeat analysis. After verification, cells were cultured for <1 month before being frozen, and all experiments were performed with <6 months of culturing. L3.6p cells were provided by Dr Isaiah Fidler (MD Anderson) (16) . RLT-PSC human pancreatic stellate cells (PSCs) were provided by Dr Ralf Jesenofsky (University of Heidelberg) (17) ; HPSC-T human PSCs were provided by Dr Rosa Hwang (MD Anderson) (18) ; LTC-14 rat PSCs were provided by Dr Gisele Sparman (University Hospital of Rostock) (19) and imPSC mouse PSCs were provided by Dr Raul Urrutia (Mayo Clinic) (20) . Both human and murine PSCs were obtained directly from the labs that isolated the cells and were functionally validated by their expression patterns in the indicated studies. All cells were grown at 37°C at 5% CO 2 . PANC1, L3.6p, LTC-14, HPSC-T, RLT-PSC and imPSC cells were grown in Dulbecco's Modified Eagle Medium (DMEM) with 1 mM sodium pyruvate and 10% fetal bovine serum (FBS). MiaPaCa-2 cells were grown in DMEM with 1 mM sodium pyruvate, 10% FBS and 2.5% horse serum. CFPAC-1 cells were grown in Iscove's Modified Dulbecco's Medium (IMDM) with 10% FBS. BxPC3 cells were grown in RPMI-1640 media containing 1 mM sodium pyruvate, 10 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and 10% FBS. Conditioned media (CM) from cells was concentrated by centrifugation using an Amicon Ultra-15 cellulose filter with a molecular weight cutoff of 3 kDa from Millipore (Billerica, MA). Chemical inhibitors against ALK5 (SB431542), p38 MAPK (SB203580) and PI3K (LY294002) were purchased from Cell Signaling Technology (Danvers, MA) and dissolved in DMSO. TGF-β1 ligand was purchased from R&D Systems (Minneapolis, MN). Gemcitabine (2, 2-difluoro-2-deoxycytidine) was purchased from the Duke Hospital Pharmacy Store Room. The hENT1 inhibitor S-(4-Nitrobenzyl)-6-thioinosine (NBMPR) was purchased from Sigma-Aldrich (St Louis, MO) and dissolved in DMSO.
Adenovirus
HA-tagged constitutively active ALK5 adenovirus (HA-ALK5 T204D ) was provided by Dr Carlos Arteaga (Vanderbilt University) (21) . The luciferase control and mouse CYR61 adenoviruses were provided by Dr Brahim Chaqour (SUNY Downstate) (22, 23) . Adenoviruses were generated and purified using the Adeno-X Maxi Purification Kit from Clontech (Mountain View, CA). Adenovirus titer was determined using the Adeno-X Rapid Titer Kit from Clontech, and cells were infected at the indicated multiplicity of infection (MOI).
Lentivirus
Lentivirus CRISPR constructs targeting hCYR61, rSmad2 and rSmad3 were made using the LentiCRISPRv2 vector (Addgene Plasmid 52961) following the GeCKO protocol (24, 25) . Briefly, the lentiCRISPRv2 vector was digested by BsmB1 and de-phosphorylated by CIP alkaline phosphatase. sgRNA target sequences were designed using the GeCKO library (24, 25) (sequences listed in  Supplementary Table S1 , available at Carcinogenesis Online), and the synthesized oligos were annealed and phosphorylated using T4 polynucleotide kinase. The annealed sgRNA target sequence oligos were ligated into the digested lentiCRISPRv2 backbone using T4 DNA ligase. The ligated DNA was transformed into One Shot Stabl3 competent cells and selected on LB-Amp plates. Each construct was sequenced to verify correct incorporation of the sgRNA target sequence into the lentiCRISPRv2 vector. To generate lentivirus for each lentiCRISPRv2 construct, a 10 cm dish of 293T cells was transfected with 4.5 µg of the respective lentiCRISPRv2 construct along with 2.25 µg PAX2, 0.75 µg pMD2.G and 18 µl Xtremegene. Media was changed on the 293T cells the morning after transfection. At 48 and 72 h later, the 293T media containing lentivirus was harvested and filtered through a 0.45 µm cellulose filter. The media was applied to MiaPaCa-2, PANC1 or LTC-14 cells with 6 µg/ml polybrene. Stably infected cells were selected using 2 µg/ml puromycin. Single cell clones were isolated for MiaPaCa-2 and PANC1 hCYR61 CRISPR to achieve knockout of expression. For rSmad2 and rSmad3, the CRISPR/Cas9 vectors were stably introduced, and the bulk populations of cells with partial knockdown were used.
Western blotting
Total cell lysates were harvested, boiled in sample buffer, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes, blocked in 5% milk in Tris-buffered saline and incubated overnight with the primary antibody of interest in 5% bovine serum albumin (BSA) in Trisbuffered saline (TBS)/0.1% TWEEN. Quantification was performed 
Microarray and RNAseq dataset analysis
Patient mRNA microarray expression data were obtained from publically available datasets on NCBI Gene Expression Omnibus (GEO) for GDS4103 and GSE43288 (26, 27) . The GDS4103 platform was Affymetrix Human Genome U133 Plus 2.0 Array. The GSE43288 platform was Affymetrix Human Genome U133A Array (GPL96). All microarray data were log 2 transformed. We queried the datasets using the gene probes listed in Supplementary 
Titer glow cell viability assay
Cells were plated in 96 well opaque plates from Perkin Elmer and treated in triplicate for 48 h with indicated doses of gemcitabine. The viability of cells was measured using the CellTiterGlo® Luminescent Cell Viability Assay from Promega (Madison, WI) and normalized to the untreated condition.
Immunohistochemistry
Immunohistochemical (IHC) staining for CYR61 was performed on paraffin-embedded tissue samples verified to be PDAC by a board-certified pathologist. PDAC tissues were de-paraffinized and re-hydrated, and antigen retrieval was performed in Target Retrieval Solution from Dako North America (Carpinteria, CA) in a 95°C water bath. Tissues were blocked with Peroxidazed 1 and Background Punisher from BioCare Medical (Concord, CA) before incubation with primary antibody for 2 h at room temperature. CYR61 antibody (Santa Cruz sc-13100) was diluted 1:25, and α-smooth muscle actin (α-SMA; Sigma-Aldrich 5228) diluted was 1:4000, both in Antibody Diluent from Dako North America. Tissues were washed in TBS with 0.1% Tween 20. Tissues were then treated with the HRP-Polymer Mach 4 detection system and Warp Red Chromagen from Biocare Medical following manufacturer's recommended protocol. Slides were counterstained with hematoxylin and Tacha's Bluing Solution from Biocare Medical. IHC was performed on tissue samples from nine PDAC patients. The study was conducted with approval of the Duke IRB, and informed consent was received.
CYR61 ELISA
The CYR61 ELISA kit was purchased from R&D Systems (DCYR10), and the ELISA was performed according to kit instructions. All patient serum samples were de-identified, and informed consent was received. The study was conducted with approval of the Duke IRB. Serum was obtained from 5 cc blood at the time of a diagnostic blood draw from subjects with confirmed PDAC.
In vitro co-culture assay
LTC-14 or imPSC pancreatic stellate cells were infected with adenovirus at indicated MOIs. After 24 h infection, PSCs were washed with phosphate-buffered saline, and media was replaced to start collecting CM. After 24 h, PSC CM was harvested and filtered through a 0.45 μM cellulose filter then applied to PDAC cells. After 24 h incubation, PSC CM was refreshed, and PDAC cells were then treated with gemcitabine for 48 h at indicated doses. Adherent and floating PDAC cells were collected for western blot analysis of cleaved caspase 3 levels.
Statistics
All statistical analyses were conducted with GraphPad Prism software. For all experiments, significance was set at P < 0.05. All in vitro experiments were analyzed using parametric statistics [twosided t test or analysis of variance (ANOVA) with indicated post hoc test] and expressed as the mean ± SEM. Microarray expression data and ELISA on serum samples were analyzed using nonparametric statistics (Mann-Whitney U, Wilcoxon matched pairs signed rank test or Kruskal-Wallis global test). Linear regression was performed on microarray data with the R 2 value, P value and slope for the line of best fit reported for each comparison. Survival curves were analyzed with log-rank statistics.
Results

CYR61 promotes chemoresistance by negatively regulating gemcitabine transport through hENT1 and hCNT3
To identify potential regulators of hENT1 and hCNT3 in the PDAC microenvironment, we analyzed a publically available microarray dataset of PDAC tumor samples (26) to identify genes whose expression significantly correlated with expression of hENT1 (SLC29A1) and hCNT3 (SLC28A3) and whose expression is significantly altered in PDAC tumor samples compared with normal adjacent tissue (Supplementary Figure 1A , available at Carcinogenesis Online). We identified 25 genes whose expression significantly correlated with both hENT1 and hCNT3 and whose expression is significantly altered in pancreatic cancer (Supplementary Table 3 , available at Carcinogenesis Online). We were particularly interested in investigating cysteine-rich angiogenic inducer 61 (CYR61) because CYR61 expression is increased in cancer and negatively correlates with hENT1 and hCNT3 expression. Additionally, CYR61 is a secreted matricellular protein that can be targeted using a neutralizing antibody, which indicates it has the potential to be targeted clinically. CYR61 is a member of the CCN family of matricellular proteins, which includes connective tissue growth factor (CTGF) and nephroblastoma overexpressed (NOV). The CCN family regulates diverse cell behaviors in a context-specific manner, primarily through interacting with integrins and heparin sulfate proteoglycans to activate downstream signaling (31) .
The mRNA expression of SLC29A1 (hENT1) and SLC28A3 (hCNT3) negatively correlated with CYR61 mRNA expression in PDAC patient samples ( Figures 1A and B) , indicating that CYR61 may play a role in suppressing expression of the nucleoside transporters that mediate cellular uptake of gemcitabine in the PDAC tumor microenvironment. CYR61 expression did not significantly correlate with the expression of other nucleoside transporters in PDAC patient samples (Supplementary Figure 1B- F, available at Carcinogenesis Online), suggesting specific regulation of hENT1 and hCNT3. To examine whether CYR61 negatively regulated hENT1 and hCNT3 expression, we used CRISPR/Cas9 technology to knockout CYR61 expression in two PDAC cell lines with high CYR61 expression. We confirmed that CRISPR knockout decreased the soluble secreted CYR61 present in the CM (Supplementary Figure 2A and B, available at Carcinogenesis Online). CRISPR-mediated knockout of CYR61 significantly increased hENT1 and hCNT3 expression in PANC1 cells ( Figure 1C; Supplementary Figure 2C , available at Carcinogenesis Online). Knockout of CYR61 also significantly increased hENT1 expression in MiaPaCa-2 cells, and increased hCNT3 expression, albeit with larger increases in CRISPR 2 cells ( Figure 1D, Supplementary Figure 2D , available at Carcinogenesis Online). In a reciprocal manner, adenovirus-mediated overexpression of CYR61 in BxPC3 and CFPAC cells, which have low basal CYR61 expression, significantly decreased hENT1 expression ( Figure 1E and F, Supplementary Figure 2E Figure 2G , available at Carcinogenesis Online).
To determine whether the CYR61 knockout-mediated increases in hENT1 and hCNT3 in PDAC cells resulted in higher cellular uptake of gemcitabine, we performed gemcitabine transport assays using radiolabeled 3 H-gemcitabine as previously described (30) . Increasing doses of the hENT1 specific inhibitor NBMPR dramatically decreased the levels of 3 H-gemcitabine transported into the cell, showing specificity of the assay and supporting hENT1 as the major gemcitabine transporter in MiaPaCa-2 and PANC1 cells (Figure 2A) . CRISPRmediated knockout of CYR61 significantly increased the amount of 3 H-gemcitabine transported into PANC1 ( Figure 2B ) and MiaPaCa-2 cells ( Figure 2C ). These data indicate that the upregulation of hENT1 and hCNT3 following CRISPR knockout of CYR61 results in enhanced cellular uptake of gemcitabine. To examine whether CYR61 regulates gemcitabine-induced apoptosis in PDAC cells, we measured cell viability in response to a dose course of gemcitabine. CRISPR-mediated knockout of CYR61 significantly decreased cell viability in response to gemcitabine in PANC1 ( Figure 2D ) and MiaPaCa-2 cells ( Figure 2F ). Additionally, CRISPR-mediated knockout of CYR61 in PANC1 and MiaPaCa-2 cells resulted in increased levels of gemcitabine-induced apoptosis as shown by an increase in the levels of cleaved caspase 3 ( Figure 2E and G) . Knockout of CYR61 increased gemcitabine-induced Bax expression and decreased Bcl-2 expression in PANC1 cells (Supplementary Figure 3A, available at Carcinogenesis Online). In a reciprocal manner, adenovirus-mediated overexpression of CYR61 in CFPAC cells decreased gemcitabine-induced apoptosis (Supplementary Figure 3B , available at Carcinogenesis Online).
CYR61 expression is increased in PDAC
Bioinformatic analysis of a microarray dataset demonstrated that CYR61 expression was increased in PDAC samples compared with matched normal adjacent tissue ( Figure 3A and B), supporting increased CYR61 expression in PDAC, consistent with a prior report (32) . Further analysis demonstrated that patients with familial PanIN precursor lesions (27) have an intermediate level of CYR61 ( Figure 3C ). Although these assessments at the mRNA level were suggestive, serum protein levels of CYR61 in PDAC patients have not been investigated. Here we demonstrate that CYR61 protein expression is significantly elevated in the serum of PDAC patients, with a mean expression of 857.5 ng/ml compared with a mean expression of 508.5 ng/ml for healthy volunteers ( Figure 3D ). Further, survival data from the ICGC PACA-AU dataset demonstrated that PDAC patients with high levels of CYR61 had a trend toward lower median survival time relative to patients with low CYR61 expression ( Figure 3E ). Median survival time for the low CYR61 group was 552 days, whereas median survival time for high CYR61 group was 427 days.
CYR61 does not regulate expression of other gemcitabine resistance factors in PDAC
While nucleotide transporters are an important mechanism for regulating entry of gemcitabine into PDAC cells, there are several additional mechanisms that regulate resistance to gemcitabine in PDAC. Deoxycytidine kinase (dCK) phosphorylates gemcitabine to its active form once it enters the cytoplasm, and low expression of dCK is associated with worse survival after gemcitabine treatment (9, 10) . Additionally, high expression of the subunits of the enzyme ribonucleotide reductase (RRM1 and RRM2), which catalyzes the conversion of ribonucleotides to deoxynucleosides, is associated with gemcitabine resistance in patients (33) (34) (35) . The expression of ATP-binding cassette transporters, which act as drug efflux pumps, is also associated with drug resistance in PDAC (36) . The drug efflux pumps ABCB1 (MDR1/P-glycoprotein) and ABCC1 (MRP1) have been linked to the resistance of PDAC cells to gemcitabine (37, 38) . CYR61 has been previously reported to regulate expression of the drug efflux pump MDR1/P-glycoprotein in renal cell carcinoma (39) , but it has not been studied in PDAC. We examined the effect of CYR61 on the expression of these factors associated with gemcitabine resistance. Either overexpression of CYR61 or CRISPR-mediated knockdown of CYR61 did not alter the expression levels of MDR1 or dCK at the protein level (Supplementary Figure 4A- C, available at Carcinogenesis Online). Additionally, there was no consistent or significant effect of CYR61 expression on the mRNA level of RRM1, RRM2 or ABCC1 (Supplementary Figure 4D-F, available at Carcinogenesis Online). Moreover, in PDAC patient samples, the level of CYR61 did not significantly correlate with expression of these gemcitabine resistance factors (Supplementary Figure 5A -E, available at Carcinogenesis Online). These data suggest that CYR61 functions to mediate resistance to gemcitabine largely through its effects on the nucleotide transporters hENT1 and hCNT3.
Pancreatic stellate cells are a source of CYR61 in the PDAC tumor microenvironment
PDAC is characterized by an abundant fibrotic stroma that can comprise up to 80% of the tumor volume (40) , making this stroma perhaps the most prominent of all epithelial cancers. This stroma contains PSCs, which are the predominant cells responsible for secretion of the extracellular matrix (ECM) components that comprise the fibrotic stroma (41) (42) (43) . The microarray dataset used to examine CYR61 expression analyzed whole-tissue tumor samples that include both cancer and stromal cells (26) , suggesting that the PSCs might be a source of CYR61. To determine whether PSCs within the tumor microenvironment secrete CYR61, we examined RNAseq data that analyzed gene expression in PDAC tumors as well as three cell population isolated from the tumor: PSCs, tumor epithelial cells grown in patientderived xenografts (PDXs) and tumor epithelial cells grown in in vitro cell culture (29) . Isolated PSCs, identified as α-SMA positive, vimentin positive and EpCam negative (29) , expressed significantly higher levels of CYR61 compared with human tumor epithelial cells in patient-derived xenografts or in vitro cell culture ( Figure 4A ). PDAC samples expressed an intermediate amount, suggesting that the CYR61 from these samples is derived partly from stromal cells present in the samples. Isolated tumor epithelial cells grown in vitro also had higher CYR61 expression than tumor cells grown in PDX (Figure 4A ), suggesting that some PDAC epithelial cells may express higher levels of CYR61 in in vitro cell culture conditions as compensation for the lack of stromal-derived factors that are present in vivo.
To investigate expression of CYR61 at the protein level, we performed IHC staining for CYR61 on human PDAC tissue. PSCs in the tumor microenvironment were identified by staining for α-SMA on consecutive slides, and α-SMA staining in muscular arterial wall and duodenal smooth muscle (muscularis propria) overlying head of pancreas was used as a positive control (Supplementary Figure 6A, In addition, we evaluated expression of CYR61 in five PDAC cell lines and two human PSC cell lines, HPSC-T (18) and RLT-PSC (17), which were isolated from PDAC and chronic pancreatitis samples, respectively. We validated the identity of PSCs by confirming expression of the PSC-specific markers α-SMA, vimentin, collagen 1α1 and desmin (Supplementary Figure 7 , available at Carcinogenesis Online). The mesenchymal PSCs expressed high levels of the ECM protein fibronectin, whereas most PDAC cells expressed higher levels of the epithelial marker E-cadherin ( Figure 4C ). The PSC cell lines had higher CYR61 expression than the majority of PDAC cell lines ( Figure 4C) . Interestingly, the PANC1 cell line also had high expression of CYR61 ( Figure 4C ). Consistent with a role for CYR61 in gemcitabine resistance, pancreatic cancer cell lines that express higher levels of CYR61 were more resistant to gemcitabine-induced apoptosis in vitro ( Figure 4D and E).
TGF-β signaling induces CYR61 expression in PSCs in the PDAC tumor microenvironment
CYR61 has been demonstrated to be regulated by both the transforming growth factor-β (TGF-β) signaling and Hippo-YAP/TAZ signaling pathways (44, 45) . TGF-β ligand expression is elevated in PDAC, and patients with high levels of TGF-β1 ligand in their serum have a significantly worse prognosis (46) . However, mutations that inactive the canonical TGF-β-Smad signaling pathway are common in PDAC, with around 55% of PDAC patients having inactivating mutations in SMAD4 (47) . Therefore, elevated TGF-β may negatively affect PDAC progression or therapy response in part through stromal cells with intact SMAD4, including PSCs. Consistent with this hypothesis, in the microarray dataset that analyzed gene expression in whole-tissue PDAC samples, CYR61 expression significantly correlated with expression of the TGFB1 ligand and also with the well-established TGF-β target genes SERPINE1 (PAI-1) and SMAD7 ( Figure 5A-C) . Moreover, in the rat PSC cell line LTC-14 (19) and the mouse PSC cell line imPSC (20) , which were isolated from normal pancreas and have low basal CYR61 expression, TGF-β induced CYR61 expression in a dosedependent fashion ( Figure 5D ). TGF-β induced CYR61 protein expression as early as 6 h post treatment and mRNA expression as early as 3 h post treatment, suggesting that the induction of CYR61 by TGF-β was a direct effect and not via induction of other growth factors ( Figure 5E and F) .
TGF-β induces activation of canonical Smad signaling in PSCs, but TGF-β also induces activation of several noncanonical signaling pathways, including p38 MAPK and PI3K-Akt signaling ( Figure 5G ; Supplementary Figure 8A , available at Carcinogenesis Online). To determine which downstream signaling pathways were important for TGF-β-induced CYR61 expression in PSCs, we pretreated PSCs with kinase inhibitors against ALK5, p38 MAPK and PI3K and examined the effect on TGF-β-induced CYR61 expression. Treatment with the ALK5 inhibitor, but not the p38 MAPK or PI3K-Akt inhibitor, blocked TGF-β-induced CYR61 expression ( Figure 5H; Supplementary Figure 8B , available at Carcinogenesis Online). We confirmed that these inhibitors blocked activation of downstream targets in the LTC-14 PSCs (Supplementary Figure 8C- 
TGF-β-Induced CYR61 promotes gemcitabine resistance in an in vitro co-culture assay
To examine the role of TGF-β-induced CYR61 in PSCs on gemcitabine-induced apoptosis of cancer cells, we established an in vivo co-culture assay where PDAC cells were treated with CM from PSCs with activated TGF-β signaling ( Figure 6A ). To examine the role of stromal CYR61, LTC-14 PSCs were infected with adenoviruses to express CYR61 or CA-ALK5 with a luciferase adenovirus used as a control ( Figure 6B ). We verified that activation of TGF-β signaling in LTC-14 PSCs through expression of CA-ALK5 releases soluble CYR61 into the CM ( Figure 6C ). CM from PSCs with CYR61 expression or CA-ALK5 protected CFPAC cells from gemcitabine-induced apoptosis as shown by reduced levels of cleaved caspase 3 ( Figure 6D ). Similar results were obtained in the BxPC3 cell line (Supplementary Figure 10C) . In contrast, expression of constitutively active YAP in LTC-14 PSCs only weakly induced CYR61 and did not affect the gemcitabineinduced apoptosis of PDAC cells in our in vitro co-culture model (Supplementary Figure 10D , available at Carcinogenesis Online), suggesting that TGF-β signaling was the primary pathway inducing CYR61 expression in PSCs. Finally, in silico analysis of whole-tissue PDAC samples demonstrated that TGFB1 ligand expression negatively correlates with expression of SLC29A1 (hENT1) and SLC28A3 (hCNT3) ( Figure 6E and F) , suggesting that TGF-β plays a role in regulating these nucleoside transporters in vivo.
Discussion
Chemotherapy resistance is a major clinical problem in PDAC. Even one of the commonly used first-line agents, gemcitabine, has a very low response rate and only modestly prolongs survival. Therefore, it is important to understand the cellular mechanisms that regulate resistance to gemcitabine. Our results demonstrate that CYR61 promotes resistance to gemcitabine predominantly by modulating the levels of the nucleoside transporters that mediate cellular uptake of gemcitabine. The role of the stroma in therapy resistance is an emerging area of interest in PDAC with recent genetic mouse models and clinical trials that target PSCs having conflicting results, with both positive and negative effects on cancer progression and response to gemcitabine (49) (50) (51) (52) . Understanding what aspects of PSCs promote therapy resistance and identifying signaling mechanisms that regulate this are important to effectively target the stroma. Here we demonstrate that stromal-derived CYR61 has an important role in promoting gemcitabine resistance through downregulation of the nucleoside transporters hENT1 and hCNT3.
We have demonstrated that TGF-β strongly induces CYR61 expression in PSCs. A recent phase II clinical trial suggested that addition of the TGF-β inhibitor galsunisertib to gemcitabine led to improved overall and progression-free survival in PDAC patients compared with gemcitabine alone (53) . Due to the pleotropic homeostatic functions of TGF-β, global inhibition of TGF-β signaling does have the potential to have side effects. Therefore, understanding the specific downstream effectors of TGF-β signaling in PDAC is important for development of future therapies. Our results indicate that stromal TGF-β signaling promotes resistance to gemcitabine in PDAC cells via induction of CYR61. TGF-β is a major driver of EMT (54) , and EMT has recently been shown to regulate gemcitabine resistance and expression of hENT1 and hCNT3 in PDAC (14) . Whether additional TGF-β-induced genes promote gemcitabine resistance through regulation of these nucleoside transporters, and whether CYR61 mediates the effects of TGF-β on EMT in PDAC (32), remains to be established.
CYR61 is a member of the CCN family of matricellular proteins, which includes CTGF and NOV. Targeting the CCN family member CTGF in combination with gemcitabine in PDAC has shown promise in a preclinical mouse model (55) , and the CTGF neutralizing antibody FG-3019 is being tested in an ongoing clinical trial (56) . However, although CTGF and CYR61 are structurally similar, the FG-3019 neutralizing antibody does not interact with CYR61 (57). The current results regarding the role of CYR61 in gemcitabine resistance provide a rationale for inhibiting CYR61 or both CTGF and CYR61 in combination with gemcitabine (and nab-paclitaxel) in PDAC patients. Although our study is the first to identify a role for CYR61 in nucleoside transporter expression and gemcitabine resistance, CYR61 has recently been implicated in therapy resistance in the contexts of several other cancers, including renal cell carcinoma (39), breast cancer (58, 59) , acute myeloid leukemia (60) and ovarian cancer (61) , which indicates that CYR61 may be a promising target to improve efficacy of chemotherapy.
In summary, here we have identified that the matricellular protein CYR61 is induced by the TGF-β-ALK5-Smad signaling pathway in PSCs in the tumor microenvironment, where it negatively regulates the expression of the nucleoside transporters hENT1 and hCNT3 in PDAC to mediate resistance to gemcitabine.
